ArticleTranslational andrology and urology2025
Personalized radiotherapy benefit prediction in non-surgically managed prostate adenocarcinoma: a prognostic nomogram for survival risk stratification.
Article in Translational andrology and urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Prostate adenocarcinoma (PCa) imposes a significant global health burden. Radiotherapy is a primary local treatment for non-surgically managed patients; however, reliable tools to predict which individuals will derive a survival benefit are lacking. This study aimed to develop a risk stratification model to evaluate survival benefits of radiotherapy in non-surgically treated PCa patients and identify subgroups likely to benefit from radiotherapy. Methods: Data from 100,155 non-surgically treated PCa patients [2004-2015] were retrieved from the Surveillance, Epidemiology, and End Results (SEER) database. All-subsets regression and multivariate Cox regression were used to construct nomograms for overall survival (OS) and cancer-specific survival (CSS), quantifying survival risk and stratifying patients into low- and high-risk groups. Subgroup analyses based on risk stratification were conducted to assess the value of radiotherapy. Results: In the whole cohort, radiotherapy significantly improved 5-year OS (84.2% Conclusions: The developed nomograms effectively identify patients likely to benefit from radiotherapy. High-risk patients experience significant OS and CSS benefits, while radiotherapy is not recommended for low-risk patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.